 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C26H26N2O5 |
| Molecular Weight | 446.50 |
| Exact Mass | 446.184 |
| CAS # | 167498-29-5 |
| PubChem CID | 10456222 |
| Appearance | White to off-white solid powder |
| LogP | 3.937 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 11 |
| Heavy Atom Count | 33 |
| Complexity | 608 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C=O)NC(=O)OCC3=CC=CC=C3 |
| InChi Key | QVDJMLQSYRSZKC-UPVQGACJSA-N |
| InChi Code | InChI=1S/C26H26N2O5/c29-17-22(15-20-11-13-23(30)14-12-20)27-25(31)24(16-19-7-3-1-4-8-19)28-26(32)33-18-21-9-5-2-6-10-21/h1-14,17,22,24,30H,15-16,18H2,(H,27,31)(H,28,32)/t22-,24-/m0/s1 |
| Chemical Name | benzyl N-[(2S)-1-[[(2S)-1-(4-hydroxyphenyl)-3-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | cathepsin L |
| ln Vitro | Pretreatment with Z-FY-CHO (10 μM) for one hour reduced the amount of cell death caused by 6-OHDA. Z-FY-CHO prevents 6-OHDA-treated SH-SY5Y cells from expressing more CTSL protein. In SH-SY5Y cells treated with 6-OHDA, Z-FY-CHO treatment increased LC3-II and decreased P62 expression, suggesting increased autophagy activity. Z-FY-CHO also inhibits the activation of caspase-3 and PARP[1]. ?U251 cells' radiosensitivity was greatly enhanced by transfection with cathepsin L shRNA or treatment with the particular cathepsin L inhibitor Z-FY-CHO (10 μM). In U251 cells, cathepsin L knockdown and suppression both exacerbated irradiation-induced DNA damage and G2/M phase cell cycle arrest. Increased levels of Bax and decreased levels of Bcl-2 demonstrate that irradiation-induced apoptosis was enhanced in U251 cells by both cathepsin L suppression and knockdown[2]. |
| ln Vivo | In an experimental model of osteoporosis involving ovariectomized mice, intraperitoneal injection of Z-FY-CHO (2.5-10 mg/kg) for 4 weeks inhibits bone weight loss in a dose-dependent manner. Z-FY-CHO suppresses bone resorption by preventing the breakdown of collagen[3]. |
| References |
[1]. Activated cathepsin L is associated with the switch from autophagy to apoptotic death of SH-SY5Y cells exposed to 6-hydroxydopamine. Biochem Biophys Res Commun. 2016 Feb 12;470(3):579-585. [2]. Cathepsin L suppression increases the radiosensitivity of human glioma U251 cells via G2/M cell cycle arrest and DNA damage. Acta Pharmacol Sin. 2015 Sep;36(9):1113-25. [3]. Suppressive effect of N-(benzyloxycarbonyl)-L-phenylalanyl-L-tyrosinal on bone resorption in vitro and in vivo. Eur J Pharmacol. 1996 Apr 4;300(1-2):131-5. |
Solubility Data
| Solubility (In Vitro) | DMSO: 100 mg/mL (223.96 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (2.80 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (2.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2396 mL | 11.1982 mL | 22.3964 mL | |
| 5 mM | 0.4479 mL | 2.2396 mL | 4.4793 mL | |
| 10 mM | 0.2240 mL | 1.1198 mL | 2.2396 mL |